News

Cerevance Achieves First Milestone in Research Collaboration with Merck

BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system…

2 years ago

Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel…

2 years ago

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a…

2 years ago

QHSLab, Inc. Enhances Leadership Team with Dr. Marcos Sanchez-Gonzalez as New VP of Medical and Scientific Affairs

WEST PALM BEACH, FL, May 02, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the "Company") (OTCQB: USAQ), a leader in digital…

2 years ago

Veru to Present at the GLP-1 Based Therapeutics Summit

MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

2 years ago

Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on…

2 years ago

IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share

Reports record revenue of $17.6 million for the first quarter of 2024.Reports GAAP diluted EPS of $0.32 and non-GAAP diluted…

2 years ago

Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today…

2 years ago

STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder

Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces…

2 years ago

Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering…

2 years ago